Deoxyspergualin: clinical trials in renal graft rejection. Japan Collaborative Transplant Study of Deoxyspergualin.
The percentage of efficacy of DSG, when used alone, was 76 percent in patients having acute rejection within 6 months after grafting. The doses of 3 to 5 mg/kg/day was judged to be recommendable and the duration of treatment of 7 days was evaluated as a suitable duration. Rescue use of DSG was effective in 70 percent of patients having MP-resistant rejection. In acute rejection, the percentage of efficacy of DSG plus MP combination was 88 percent. In addition, we should note that the percentage of efficacy of DSG was 66 percent even in acute or chronic rejection. The main adverse reactions with DSG included a sensation of numbness of the face, lips, and limbs, gastrointestinal troubles, and bone marrow suppression, but these adverse reactions were not serious. DSG has a mechanism of action different from that of other immunosuppressive agents, and it has fewer adverse effects than other drugs. Different from biological preparations, DSG is a strong immunosuppressive agent that can be used repeatedly.
Amemiya
H
H
Department of Surgical Research, National Cardiovascular Center, Osaka, Japan.
D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male
D006146:Guanidines; D007166:Immunosuppressive Agents; C037258:gusperimus